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Drug-Eluting Medical Textiles: From Fiber Production and
Textile Fabrication to Drug Loading and Delivery
Matin Rostamitabar, Abdelrahman M. Abdelgawad, Stefan Jockenhoevel,
and Samaneh Ghazanfari*
Drug-eluting medical textiles have recently gained great attention to be used
in different applications due to their cost effectiveness and unique physical
and chemical properties. Using various fiber production and textile fabrication
technologies, fibrous constructs with the required properties for the target
drug delivery systems can be designed and fabricated. This review
summarizes the current advances in the fabrication of drug-eluting medical
textiles. Different fiber production methods such as melt-, wet-, and
electro-spinning, and textile fabrication techniques such as knitting and
weaving are explained. Moreover, various loading processes of bioactive
agents to obtain drug-loaded fibrous structures with required
physicochemical and morphological properties, drug delivery mechanisms,
and drug release kinetics are discussed. Finally, the current applications of
drug-eluting fibrous systems in wound care, tissue engineering, and
transdermal drug delivery are highlighted.
1. Introduction
The market of medical textiles has great potential as it was worth
USD 13.94 billion in 2014, which constituted 10% of the technical
textile market in Europe and was predicted to increase its share
to about 12% in the near future.[1,2] Various textile features such
as their flexibility, light-weight, wide range of dimensions, sur-
face, physical, and structural properties made these constructs
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favorable to be used in different med-
ical applications.[3,4] Textile fabrics have
been extensively used as drug delivery sys-
tems in wound dressings, synthetic skin
graft substitutes, scaffolds for tissue re-
pair and regeneration, and other topical
applications.[4,5]
Textile fibers are categorized into natural
and man-made groups based on their
origin or the way they have been produced.
Natural fibers refer to naturally occurring
fibers found in animals, vegetables, and
minerals in which their properties depend
on the source, the region where they have
been produced or stored.[6,7] On the other
hand, man-made textile fibers do not occur
in nature although they might be made
from natural materials in which the phys-
ical and chemical properties of the initial
material have been altered notably during
processing. Man-made fibers can be made from synthetic and
natural materials.[7,8] These fibers can be manufactured using dif-
ferent fiber production methods, such as melt spinning,[9] wet
spinning,[10] and electrospinning[11] depending on the material
used and the properties required for the final fibrous construct.
The cross-sectional shape of the fibers has a significant in-
fluence on their physical and mechanical properties, such as
flexural rigidity, crispness, and stiffness.[12] Various shapes have
been observed in natural fibers. For example, silk fibers have
a triangular shape with rounded edges, while wool fibers have
oval to round cross-sectional shapes.[13,14] Man-made fibers re-
sulting from different production methods can also have differ-
ent cross-sectional forms such as round, trilobal, and crenulated,
and various morphologies, such as hollow and porous.[5,15,16]
In addition, different types of polymers can be combined to
produce fibers with the properties required for different med-
ical applications. For example, synthetic and natural polymers
can be combined as the natural polymer can provide biological
recognition and the synthetic polymer can be used for tuning
the mechanical properties.[17] This combination can also appear
in various morphologies, including core–shell structures,[18,19]
micro/nanotubes, interpenetrating phase morphologies,[20] and
nanoscale geometries, such as spheres, rods, micelles, lamellae,
vesicle tubules, and cylinders.[21] Finally, produced fibers can be
assembled into a 3D construct as woven, knitted, braided, or non-
woven.
In woven textiles, the fibers are intermeshed together through
a pattern called “warp” and “weft,” which typically results in a
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more robust and dimensionally stable structure than nonwoven
structures.[22] However, in nonwoven textiles, no interwoven
strands exist and fibers are bound by applying heat, chemicals,
pressure, or a combination of these methods. The mechanical
and thermal properties can be tuned by orienting fibers ran-
domly or favorably in specific directions;[5,23,24] therefore, suitable
constructs for various biomedical applications, such as wound
care,[25] and skin grafts,[26] can be obtained. Finally, both woven
and nonwoven constructs can be functionalized with different
bioactive agents using different drug loading methods.[27]
Fibers can be loaded with bioactive agents or drugs using
suitable physical or chemical processes. Examples of physical
drug loading methods are absorption or adsorption, coating, and
encapsulation, and examples of chemical loading methods are
covalent conjugation and grafting.[4,28–31] Fibrous textiles used
for drug delivery can also be categorized based on the mech-
anism by which the drug is released.[32] Some major types of
releasing mechanisms are drug or solvent diffusion-controlled
systems,[33,34] chemically controlled systems, such as enzymatic
or hydrolytic degradation,[35] and externally regulated systems in
which the application of an external stimulus, such as ultrasound
or electrical field, triggers the release of the drug.[36,37] The re-
lease mechanism of the drug-containing fibers as a drug delivery
system can be engineered based on the final application to avoid
unwanted results, such as burst effect.
To investigate the kinetics of drug release, various statistical
methods, such as repeated measures design,[38,39] and model-
dependent approaches, such as zero-order model,[40,41] have been
developed based on the different phenomena which control the
drug release profiles.[42] Among various kinetic models, the zero-
order is commonly used as it provides a consistent delivery pace
of the drug independent of the concentration.[40] Another sim-
ple and frequently used model of drug release kinetic is the
Korsmeyer-Peppas Model, the so-called power law, which de-
scribes the fractional amount of the drug released over time based
on the assumption that the drug diffuses through the polymer or
the solvent diffuses inside.[41] Other models take more parame-
ters, such as the effect of desorption, degradation, concentration
gradient, and porosity, into account and thus providing more ac-
curate outcomes.[11,43,44]
Developing pioneering biomaterials with tunable physical and
chemical properties that are qualified to provide controlled deliv-
ery of different biomolecules has great importance in the field
of biomedical engineering. In this review, the materials, produc-
tion, and fabrication of drug-eluting fibers, mechanisms of drug
loading and delivery systems, and ultimately different biomedi-
cal applications of drug-eluting textiles are discussed. Finally, the
benefits and drawbacks of different types of drug-eluting textiles
and mechanisms of drug loading and release kinetics are sum-
marized and potential future directions are provided.
2. Classification of Fibers and Materials
The main structural elements in textile products are made from
natural and manufactured fibers. Natural fibers are sorted de-
pending on their resource, originating from plants, animals, or
minerals.[4] The most frequently used natural fibers in medical
products are cotton, silk, and flax.[45,46] In addition, manufactured
or man-made fibers can be divided into organic and inorganic
fibers. Organic fibers can be further categorized into two large
groups based on their sources which can be either natural or
synthetic polymers.[5,14,47] Textile fibers classification, including
some examples from each group, is shown in Figure 1.
2.1. Materials
By considering the difference in intrinsic functionality and phys-
iochemical properties of various materials, selection of the right
material or polymer plays a crucial role in designing and devel-
oping eluting drug textile. Natural, synthetic polymers, and inor-
ganic compounds can be spun into fibers and form drug-eluting
textile for versatile biomedical applications with varying proper-
ties, including macromolecule–drug interaction, drug loading ef-
ficiency, and release profiles.[48]
2.1.1. Natural Polymers
Natural polymers are widely present and produced in living
organisms and are used in numerous fields such as tissue
engineering,[49,50] the food industry,[51,52] and the pharmaceutical
industry.[53,54] Natural polymers are biodegradable, biocompat-
ible, low/nontoxic, relatively inexpensive, and readily available
in many parts of the world.[55,56] However, they have some draw-
backs, such as batch-to-batch variations, an uncontrolled hydra-
tion rate, and a slow production rate.[56,57] Natural polymers are
obtained directly from living organisms, such as carbohydrates
and proteins, and those made from renewable resources that
need to be polymerized, such as lactic acid and triglycerides.[58,59]
Carbohydrate polymers or polysaccharides are polymerized
out of monosaccharides. Polysaccharides have a high molec-
ular weight and can possess different charges or pH values.
Various 3D structure of these macromolecules is governed by
the linkage configuration of monomers.[60,61] The most well-
known carbohydrate polymer is cellulose, which is typically ob-
tained from processed cotton, wood pulp, or bacterial sources.[62]
Cellulose and its derivatives are utilized for applications such
as wound dressings due to their high tendency to form blood
clots.[63,64] Furthermore, fibers obtained from modified polysac-
charides such as alginates from algae, chitosan from crustacean
shells, hyaluronan from the extracellular matrix (ECM), dex-
tran, and reticulated cellulose from bacterial fermentation are
used for biomedical applications. Examples of polysaccharide-
based products are wound dressings from alginate or bacterial
cellulose,[65,66] surgical sutures made out of cellulose, alginate or
chitosan,[67,68] scaffold materials or implants from chitosan, cel-
lulose, or hyaluronan.[69,70]
Protein-based fibers have been commercially produced since
the 1950s.[71] Protein-based fibers are widely used in medical tex-
tiles to possess biological recognition for cells to adhere to and
promote cell infiltration and proliferation compared to carbohy-
drates and synthetic polymers.[5,72] Protein-based fibers are ob-
tained from living organisms using two main methods. In the
first method, proteins are dissolved by solvents or enzymes be-
fore being precipitated and reconstituted into fibrils. In the sec-
ond approach, other elements of living organisms are removed by
solvent or enzymes.[73] Natural proteins such as collagen, gelatin
from thermal denaturation or acid/alkali degradation of collagen,
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Figure 1. Classification of textile fibers and materials. Fibers are divided into two main categories of natural and man-made fibers, each of which has
several subgroups as shown in the figure.
fibrinogen, glycoprotein, and elastin have been extensively used
to produce medical textiles.[55,58,74,75]
Natural polymers can be modified via their functional groups,
such as amino carboxylic and hydroxyl groups, to improve their
functionality, such as solubility, using chemical[51] or enzymatic
modifications.[52] For example, chitosan, the deacetylated form
of chitin, is a water-soluble polymer at a low pH, while chitin
is insoluble in typical regular solvents such as water, organic
solvents, mild acidic or basic solution.[76] Fibers spun from some
natural polymers lose their mechanical properties in the human
body typically faster than required. Thus, hybrid materials are
preferred when using natural-based polymers, especially pro-
teins, to reach the desired physical properties and improve the
processability.[5,77–80]
2.1.2. Synthetic Polymers
Synthetic fibers are typically produced from chemicals or petro-
chemicals based materials. Through various polymerization
processes, long molecular chains can be formed with different
molecular weights and functional groups.[81] Therefore, engi-
neering the structural characteristics of the material, such as
melting point, crystallinity, and the glass transition tempera-
ture, can lead to medical textiles’ advancement and innovation.
Three class of widely used synthetic fibers which dominate
the market are nylon, polyester, and acrylic.[82] Other popular
synthetic polymers such as poly lactic-co-glycolic acid (PLGA),
polycaprolactone (PCL),[83] polyethylene oxide (PEO),[84] and
water-soluble polymers, such as polyvinyl alcohol (PVA),[85]
poly(N-vinylpyrrolidone) (PVP),[86] are used to fabricate drug-
eluting textiles for versatile biomedical applications. There are
some challenges with biocompatibility and biodegradability of
synthetic fibers, however, they are more preferred than inorganic
materials due to carbon element-based nature, which is more
similar to the structure of biological tissue.[87]
2.1.3. Inorganic Materials
The inorganic fibers are composed mainly of inorganic chem-
icals, such as alumina, aluminum, carbon, silicon, and boron,
which can be shaped into fibers after processing at elevated
temperatures.[88] Inorganic fibers usually have high thermal and
mechanical resistance. Many inorganic fibers, such as carbon
nanotube, hydroxyapatite, and glass, have been successfully used
in biomedical applications such as artificial hips,[89] and vascular
stents.[88,90] Figure 1 shows a summarized schematic of fiber clas-
sification.
3. Classification of Drug-Eluting Textiles
Drug-eluting medical textiles can be divided into three leading
categories of filament fibers, woven, and nonwoven fabrics. Such
textiles can be degradable or nondegradable based on the nature
of the base polymer from which they are made. Among these
three categories, nanofiber nonwovens have attracted more at-
tention in recent years and have been extensively developed for
various biomedical applications using different polymers. Addi-
tionally, individual fibers produced in the form of continuous fil-
aments have been of great interest too. Such fibers may contain
the active bio-agents inside or chemically bond to their surface.
Braided surgical suture for wound closure is an example of mono
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Figure 2. The schematic of fiber production techniques and their representative morphologies. A) Melt-spinning method in which the molten polymer
is extruded through the spinning head. B) Wet-spinning process showing that the polymer solution is extruded through a spinneret into an anti-solvent
to form a solidified fiber. C) Electrospinning in which polymer solution or melt is subjected to an electric field to fabricate micro or nanofibers, and D)
some examples of various morphologies of multicomponent fibers.
and multifilament fibers. Such continuous filaments are usually
manufactured using two main techniques of melt spinning and
wet spinning based on whether the polymer is spun in melt or
solution state.[11,91–93]
Typically, natural fibers have diameters ranging from 10 to 100
µm, and manufactured fibers, using melt or wet spinning, could
reach a similar diameter range. However, by using the electro-
spinning method, the size of produced fibers could decrease to
the nanometer scale.[5] Nevertheless, electrospinning is consid-
ered as a textile manufacturing technique rather than a fiber pro-
duction method since nonwoven mats are the output products
and not single fibers. Ultimately, multicomponent spinning is
an approach to combine two or several polymers in the spin-
ning head using the aforementioned techniques which enables
us to obtain fibers with a wide range of biological and mechanical
properties.[94] Different classes of drug-eluting textiles including
various fabrication technologies are discussed in the following
section.
3.1. Fiber Production Methods
3.1.1. Melt Spinning
During melt spinning, the polymer granules or resin is heated
within an extrusion to reach the melting point. The molten poly-
mer is then extruded through the spinning head, and based on
the number of spinneret holes, either mono- or multifilament is
obtained (Figure 2A).[91] The geometry of the spinneret defines
the cross-sectional appearance of the fibers which can be, for in-
stance, round or trilobal hollow.[5,91] Fibers are then cooled and
solidified in the air and further post fabrication processes such
as drawing, lubricating, twisting, or entangling prior to being
winded on a bobbin can be applied on them.[4]
Melt spinning is typically performed using thermoplastic poly-
mers with high degradation temperatures and low melt viscosi-
ties. Therefore, it is not possible to use this technique for some
natural polymers, such as chitin or chitosan, due to the strong
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interchain forces that raises the melting point above the thermal
degradation or the thermal sensitivity of the backbone.[95] How-
ever, polymers from renewable sources like poly(l-lactic acid)
(PLA),[96] poly(𝜖-caprolactone) (PCL),[97] and cellulose derivatives,
such as cellulose acetate butyrate,[98] can be spun using this tech-
nique. Finally, due to the high processing temperature, melt spin-
ning is typically not suitable for fabricating drug-loaded fibers,
especially when the drug is impregnated into the fibers during
the spinning process.[99]
3.1.2. Wet/Gel Spinning
In wet spinning, the polymer solution is extruded through
a spinneret into an antisolvent in a regeneration bath where
the fluid coagulates and regenerates into continuous solid fil-
aments. Afterward, solvent and antisolvent are washed, and
fibers are drawn and dried before winding (Figure 2B). Dry-
jet wet spinning is similar in principle to wet spinning; how-
ever, the only difference is that the polymer solution will be
spun through an air gap before reaching the antisolvent regen-
eration bath, causing higher molecular chain orientation com-
pared to wet spinning.[100,101] Due to the diffusion of the sol-
vent into the antisolvent, the cross-sectional shape of the fibers
is often crenulated with multiple grooves.[5,24,102] Cellulose (vis-
cose rayon),[19] chitosan,[24] alginate,[103] and PCL[104] are some
examples of natural polymers that have been spun using this
method.
The spinneret diameter, air pressure, injection rate, concentra-
tion of the polymer, and the type of solvent and anti-solvent have a
noteworthy impact on the characteristics of the final fibers.[24,105]
For example, wet spun alginate hydrogel wound dressings with
different fiber size (≈55–170 µm), Young’s modulus (0.026–0.148
MPa), swelling ratio, release efficacy, water vapor transmission
rate, and antibacterial activity were manufactured only by chang-
ing the spinning parameters such as air pressure (3–6 bar), con-
centration of alginate and calcium (1.5 to 3 w v–1% alginate; 0.5 to
5 w v–1% calcium), and nozzle diameter (150–200 µm). The con-
trol sample (≈60 µm diameter) was spun with the air pressure of
6 bar, needle size of 150 µm, and calcium and alginate concentra-
tion of 5 w v–1%, 1.5 w v–1%, respectively. In this study, the lower
pressure or lower injection rate and longer manufacturing time
formed loosely bound large-diameter fibers (≈160 µm, E = 0.04
MPa), as it allowed more time for calcium to crosslink the fiber.
The ten-time decrease in the calcium concentration (0.5 w v–1%)
led to the fabrication of thicker fibers (80 µm) since the alginate
molecules had more time to expand before complete crosslinking
occurred.[106]
Furthermore, coaxial wet-spinning fabrication can be utilized
to create core–shell fibers as a method to impregnate both hy-
drophilic and hydrophobic drugs in one structure. For instance,
Wade et al. produced coaxial alginate–PCL microfibers, which
were loaded with gemcitabine and nab-paclitaxel in the alginate
core and PCL shell, respectively in order to treat unresectable
pancreatic ductal adenocarcinoma. More than 94% of the gem-
citabine was released in the first 10 h in the simulated body fluid
(SBF) and phospholipase D, while nab-paclitaxel exhibited a sus-
tained release profile over three weeks with less than 39% of the
drug released in PBS.[107]
3.1.3. Electrospinning
The first usage of electrospinning to fabricate microfibers and
nanofibers goes back to 1934, where Formhals released his work
on artificial threads using the electrostatic procedure.[108] In
this method, fibers with diameters ranging from micrometer to
nanometer from a polymer solution or melt subjected to an elec-
tric field can be fabricated. The electrospinning system is com-
posed of a syringe pump that controls the flow rate of the solution
and a high voltage power supply connecting an electrode with a
needle-like nozzle to a collector electrode (Figure 2C).[11,109–111]
The final properties of the fibers are influenced by different
processing variables such as voltage, nozzle to collector distance,
needle diameter, flow rate, spinning ambient, and solution pa-
rameters, such as concentration, viscosity, conductivity, surface
tension, and solvent volatility. Fiber orientation can be controlled
by selecting the proper collector for a specific end application. Ro-
tating drums or parallel plates can be used to produce fiber mats
with aligned and unoriented fibers, respectively.[112] For example,
for the fabrication of the scaffolds for vascular grafts, it is essen-
tial to produce tubular constructs with the fibers predominantly
aligned in the circumferential direction mimicking the preferen-
tial alignment of the ECM fibers in native blood vessels.[63,113]
The possibility of incorporating hydrophobic and hydrophilic
drugs/proteins and metallic nanoparticles within the bulk phase
of fibers makes electrospinning an efficient and highly flexi-
ble process to produce drug-eluting fibers.[11,114] We reported
the loading and controlled release of tetracycline hydrochlo-
ride (TC.HCl) from Curdlan nanofibers over a period of 6
h.[115] Curdlan, an extracellular polysaccharide produced by Al-
caligenes faecalis bacterium, was blended with polyethylene ox-
ide in different ratios. Antimicrobial activity was acquired
by loading TC.HCl to the fibrous system. The cross-linked
nanofibers showed an initial burst release behavior in the
first 2 h due to the release of TC.HCL attached to the sur-
face of poly(ethylene oxide) (PEO) nanofibers. Afterward, a sus-
tained release profile over 6 hours was observed. Several other
polymers, such as PLA,[116] gelatin,[117] PCL,[118] and polymers
from bacterial sources, such as polyhydroxyalkanoate,[119] poly(3-
hydroxybutyrate-co-3-hydroxyvalerate),[120] can be used to pro-
duce ultrafine fibers using electrospinning.
Moreover, a summary of spinning feed type and parameters
as well as the resultant cross-sectional shape of the fibers using
three spinning methods of melt spinning, wet spinning, and elec-
trospinning are provided in Table 1.
3.1.4. Multicomponent Spinning
Multicomponent spinning technology can provide the oppor-
tunity to tune the mechanical and the biological properties of
the fibers by, for example, combining a material with desired
mechanical properties for the final use with another mate-
rial possessing proper biological properties. Multicomponent
spinning requires combining two or more polymers at the
spinning head while the resulted fibers contain all the polymer
components in isolated pieces of the cross-section.[94,122] Melt-
spinning, wet spinning, and electrospinning can be utilized to
form multicomponent fibers.[11,123,124] Moreover, it is possible
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Table 1. An overview of spinning methods, processing parameters, and the resultant fiber shape.[13,112,121]
Spinning methods Feed type Process parameters Cross-sectional shape
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- Similar to melt or wet spinning - Segmented Pie
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a)
Mw (weight average molecular weight), PDI (polymer dispersity index).
to fabricate ultrafine fibers by multicomponent fiber spinning,
using thermal treatments or dissolutions to remove the polymer
matrix of some of the components of the fibers.[5,122,125]
Bicomponent spinning is used to produce nanofibers via
two essential techniques: i) spinning islands-in-the sea (INS),
which contains a large number of islands surrounded by the
sea (matrix) polymer, and ii) splittable bicomponent fibers,
known as segmented pie fibers, which is another approach to
produce nanofibers with noncircular cross-section.[122,124,126]
Furthermore, bicomponent fiber spinning can be used to spin
a resorbable polymer sheath around a nondegradable polymer;
drugs and bioactive agents can be loaded into the outer re-
sorbable sheath and released at controlled rates based on the
polymer thickness, molecular weight, and morphology.[127,128]
Multicomponent fibers containing bioactive agents or
function-regulating biomolecules, such as DNA and growth
factors, are widely used in biomedical textiles.[5,123,129] They offer
various fiber morphologies, such as core-sheath,[18] side-by-
side fibers,[130] micro/nanotubes, and interpenetrating phase
morphologies[20] as shown in (Figure 2D). In addition, a large
group of nanoscale morphologies[21] such as spheres, rods,
micelles, lamellae, vesicle tubules, and cylinders are fabricated
by self-assembly of block copolymers.[123,131] Therefore, multi-
component spun fibers have great potential to be designed and
fabricated as drug-eluting fibers.
Each aforementioned fiber spinning methods have advantages
and disadvantages for producing drug-eluting textiles. For in-
stance, melt and wet spinning methods typically lead to fibers
with larger diameters compared to electrospinning; however, an
additional fabrication process is usually required to turn fibers
into textiles. In addition, melt spinning is considered as a fast
solvent-free technique, but the degradation of polymers and in-
corporated drugs are likely to happen due to the harsh process-
ing conditions such as high temperature and shear rates. Also,
extended exposure to organic solvents during the spinning and
regeneration might in wet spinning negatively impact the fiber
biocompatibility, but it is applicable to many natural-based poly-
mers and benefit from mild temperature processing conditions.
Although electrospinning is a simple, inexpensive technique re-
sulting in submicron fibers, the toxicity of the solvents and the
instability of the jets, and the processing issues with conductive
polymers can be highly challenging.[99,132]
3.2. Textile Fabrication Techniques
Textiles as the final processed products of the fibers are typically
categorized to woven or nonwoven fabrics which are reviewed in
this section.
3.2.1. Knitted Fabrics
The knitting process creates forming loop stitches in rows (lon-
gitudinal direction of fabrics). These stitches intermesh with the
next and previous rows and form either flat or tubular fabrics.
Unlike weaving, where yarns are always running straight both in
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Figure 3. Knitted and woven fabrics in drug delivery applications. A) Schematic drawings of different knitting patterns, (I) warp knitted, (II) weft knitted.
Reproduced with permission.[134] Copyright 2000, Elsevier, and (III) weft knitted stent for treatment of colorectal cancer are presented. Reproduced
with permission.[136] Copyright 2013, Elsevier. B) Schematic drawings of different woven patterns, plain (I), twill (II), stain (III), basket (IV). Reproduced
with permission.[148] Copyright 2000, Elsevier. C) SEM images of chitosan-silver nanoparticles (I), untreated woven cotton (II), and loaded woven
cotton fabrics with nanoparticles (III, IV). Reproduced with permission.[144] Copyright 2020, Elsevier. D) SEM images of microgel particles from poly(N-
vinylcaprolacta65m) and chitosan were prepared in calcium carbonate templates (CaCO3) (I), TEM image of porous CaCO3 (II), CLSM images of microgel
after core removal (III), pure cotton fibers (IV), microparticle-loaded cotton (V), and microgel-loaded cotton (VI). Reproduced with permission.[146]
Copyright 2017, Elsevier.
the transverse (warp) or the longitudinal (warp) directions, the
yarn in knitted fabrics follows the forming sequence of symmet-
ric loops above below the mean path of the yarn. These knitted
loops are extensible in the course and wales (X and Y, respec-
tively) directions, giving the knit fabrics much more elasticity
than woven fabrics. Therefore, it is commonly used in medi-
cated bandages and adhesive tapes.[133] Depending on the loops’
formation direction, the knitting process is categorized into two
main classes of warp and weft knitting (Figure 3A-I,II).[134]
More fibers are involved in the knitting process than any
other textile technology to allow the fabrication of complex 2D
and 3D structures.[135] Li et al. developed a weft-knitted stent for
colorectal cancer treatment from 5-fluorouracil (5-FU)-loaded
polydioxanone membrane.[136] 5-FU was incorporated into the
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nanofibers and coated onto the surface of the knitted stent. The
half-maximal inhibitory concentration (IC50) and the median
lethal dose (LD50) validated that the membranes outperformed
the pure 5-FU and exhibited higher antitumor activity due
to the sustainable drug-releasing profile of the coated stent
(Figure 3A-III).
Shanmugasundaram et al. developed wound-healing flat-
knitted cellulosic fabrics coated with chitosan and alginates.[137]
Chloramphenicol and tetracycline hydrochloride drugs were
loaded into the coating polymers to improve the antibacterial
and wound healing properties. A gel-like with chunky-complexed
granules was formed; consequently, heterogeneous films were
created upon mixing chitosan and alginates due to the electro-
static interactions between the amino groups in chitosan and the
carboxyl groups in alginate. The study concluded that when the
drug on the fabric’s surface is exhausted, the polymer coating on
the surface provides a succeeding shield against bacteria.
In another study, an anti-inflammatory dressing was de-
veloped via eluting hydrocortisone (HCr) on activated cotton
knitted fabrics for skin-friendly treatment of coetaneous.[138]
Drug elution was attained either via covalent grafting of cotton
with monochloro triazinyl-beta-cyclodextrin (MCT-𝛽-CD), or
through the inclusion of sodium sulfate in an ionic crosslinked
chitosan-based hydrogel. The developed systems were deposited
on the knitted fabrics and are meant for temporary generation of
HCr inclusion. Although the drug-loading method is different,
the drug-release mechanism is relatively identical. In the case of
MCT-𝛽-CD, the wet conditions, due to perspiration, triggers the
substitution of HCr from the internal hydrophobic cavity and
promote its transfer to the dermis. For the hydrogel, the medium
swells the chitosan-based hydrogel to form a mesh, and then the
drug is diffused toward the dermis.
3.2.2. Woven Fabrics
The woven fabric is made by linking two orthogonal arrays of
yarns, the first is the warp at 0° and the second is weft at 90°.[139]
The yarns are seized in place due to the interyarn friction. The
weaving loom technology is well established and provides low
manufacturing costs through high productivity rates. The yarns’s
interlacement acquires stability to the structure and enables com-
plex shape with no gaps. Different woven structures such as
plain, twill, stain, and basket weaving are shown in Figure 3B. In
some medical applications, woven systems involve the assembly
of fabrics that are encapsulated with drugs or active ingredients.
Besides woven fabrics can be decorated with bioactive agents via
physical absorption and coating or with the aid of modifiers to
bond them covalently.[93] Apart from drug-releasing properties,
medicated woven fabrics offer defined geometry, pore structure,
as well as the strength that suitable for various medical applica-
tions such as wound dressing, artificial skin grafts, and scaffolds
for tissue engineering.[140,141]
Aykut et al. investigated the weaving of polyvinyl alcohol yarn
and cotton to produce a high-strength drug delivery system. The
woven fabrics were treated with different concentrations of aque-
ous crosslinkers, namely borax and glutaraldehyde solutions.[142]
In another study, woven cotton and viscose-micromodal fab-
rics were loaded with caffeine nanoparticles for transdermal
antioxidant patches. Once worn next to skin, the system can
deliver caffeine for several hours without any further action from
the patient.[143] The self-assembled coating on woven cotton
fabrics utilizing the layer-by-layer (L-B-L) technique to acquire
antimicrobial property was explored by Gadkari et al.[144] In this
study, chitosan loaded with silver nanoparticles (Figure 3C-I)
was used to coat the surface of the fabrics (Figure 3C-II–IV). The
sustained release of silver ions (Ag+) from cotton fabrics was
confirmed by atomic absorption spectroscopy over 48 h.
Bioactive woven cotton gauze is suitable for antimicrobial
wound dressings; for instance, medical gauze was decorated with
silver nanoparticles and medicated via acacia gum. The woven
fabric was found active against the infectious bacterial strains
Staphylococcus aureus and Pseudomonas aeruginosa. [145] Synthetic
polyester fabric has been investigated as a carrier for skin lubri-
cation via polytherapeutic substances. The loaded materials in-
creased the durability and abrasion resistance of the textile fabric
in addition to its medical effect.[93]
In another study, the microgel particles from poly(N-
vinylcaprolactam) and chitosan were prepared in calcium carbon-
ate templates (CaCO3) (Figure 3C-I–III) to be on woven cotton
fabrics for treatment of sunburn (Figure 3C-IV–VI).[146] The in
vitro drug release behavior, in response to temperature, was eval-
uated at pH 7.4 in phosphate buffer saline. The drug-release pro-
file exhibited extended-release above the lower critical solution
temperature due to the shrinkage of the microgels. Mihailiasa
et al. reported the mobilization of hyperbranched polymers on
the surface of woven cotton fabrics. Nanosponges from hyper-
branched 𝛽-CD were loaded with melatonin in water/ethanol sus-
pension and mobilized on the surface of the fabrics.[147] A zero-
order kinetic behavior was observed for the functionalized fabrics
as indication of a typical reservoir diffusion-controlled system.
3.2.3. Nonwoven Fabrics
In general, nonwovens are widely used as medical textiles and are
usually considered disposable products. Surgical gowns, masks,
surgical drapes, pads, medical filters, and wound dressings can
be made from nonwoven fabrics. Its high flexibility, short produc-
tion cycles, and low-cost production are popular reasons for us-
ing nonwovens in medical applications. During the past several
years, melt-blowing (Figure 4A), solution blowing (Figure 4B),
needle-punching (Figure 4C), air laying, wet laying, chemical
bonding, thermal bonding, hydro-entangling, spunbonding, and
carding have been essential technologies for the formation of
nonwovens for medical applications.[149,150]
Most nonwoven fabrics are anisotropic, meaning having more
fibers are oriented in longitudinal (machine direction) than the
cross direction. The fibers entanglement in a web has a pro-
found effect on the final web properties. Also, fiber configura-
tion impacts fiber packing pore size, capillary dimensions, and
capillary orientation. Although nonwovens possess several ad-
vantages when used as medicated wound dressing, such as op-
timal fluid absorbency, breathability, excellent barrier properties,
lightweight, and comfort contact with skin, they inherit weak me-
chanical stability when compared with woven and knitted fabrics.
This is mostly attributed to the lack of fiber interlacing and yarn
locking.[151]
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Figure 4. Schematic representation of some nonwoven manufacturing technologies from bulk fibers as well as nanofiber. A) Melt-blowing. B) Solution
blowing. Reproduced with permission.[150] Open access, Copyright “Creative Commons CC BY license”, 2020, Wiley. C) needle-punching. D) Immer-
sion electrospinning. Reproduced with permission.[153] Copyright 2020, Elsevier. E) Centrifugal spinning (I). Reproduced under the Creative Commons
Attribution-NonCommercial 3.0 Unported Licence.[164] Copyright 2017, The Authors, published by the Royal Society of Chemistry, (II) an image of ethyl-
cellulose/polyvinyl pyrrolidone fibers fabricated from centrifugal spinning, (III) SEM images indicating micro- and nano-porous structures produced by
centrifugal spinning. Reproduced with permission.[165] Copyright 2017, Elsevier.
The most recent nonwoven innovation is the fabrication of
2D and 3D nanofiber mats for implantable scaffolds, biologi-
cal filters, and drug-eluting systems. Recent advances in mate-
rial science enabled the materials and devices to be fabricated in
nanoscale. The primary reason for minimizing the object size
compartments to nano scales is to provide superior mechanical
properties and high surface-to-volume ratio.[152] Electrospinning
has been widely investigated to produce nanoscale fibrous struc-
tures in various conditions such as immersion electron spinning
in which the fiber collectors can be immersed in coagulant so-
lutions (Figure 4D), and the fibers can be collected in the wet
state. Different active materials such as drugs can be dispersed
in the coagulation bath and loaded to the nanofibers upon its
precipitation.[153]
Different techniques are being used for nanofiber formation,
among which biocomponent extrusion is widely used. In this
technique, two different polymers with various blending ratios
are spun together in the same fiber from the same spinneret.
Usually, one fiber component can be removed by heat, solvent,
or mechanical device, leaving the core fiber alone.[154] Another
fiber formation process is the phase separation technique. It is a
five-stage procedure in which polymer is dissolved in a proper sol-
vent followed by gelation, solvent extraction, freezing, and freeze-
drying. This system relies on phase separation due to physical in-
consistency between solvents and polymer. The dissolving agent
is extracted and leaving the residual fibers dry.[155] On the other
hand, nanofibers from polymer melts can be produced through
the melt-blowing technology. Nanofibers can be created by ex-
truding molten polymer into pressurized gas/air streams. Fur-
thermore, self-bonded webs can be collected on a rotating drum
or belt. The air jet creates a drag force attunes the fibers rapidly
and dramatically reduces its diameter below the nozzle diameter.
Nagy et al. investigated the production of a melt-blown
nanofiber system based on a hydrophilic vinylpyrrolidone-
vinyl acetate copolymer and PEO plasticizer for drug delivery
applications.[156] In addition, the blowing of polymer solu-
tions through concentric nozzles can lead to the formation of
nanofibers. Solution blow spinning was first developed in 2009
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by Medeiros et al.[157] to fabricate submicron fibers at a high
production rate. Nonwovens from PLA as well as PLA/poly(vinyl
pyrrolidone) blend containing 20% (wt/wt) antimicrobial Co-
paibla oil.[158] A recent emerging method for nanofiber formation
is centrifugal spinning (Figure 4I).[159] This spinning method
relies on centrifugal forces to achieve the high production rate
of nanofibers. Both polymer solution and melt can be used to
fabricate nanofibers.[160] Stojanovska et al. were the first to report
the formation of lignin-based nanofibers via an industrially
scalable centrifugal spinning system.[161] The research aimed at
the large-scale production of lignin/thermoplastic-polyurethane
(TPU) nanofibers for bioactive materials. In another recent study
by Rampichova et al., a 3D PCL scaffold was loaded with a com-
bination of TGF-𝛽, IGF, and bFGF growth factors and was used
as a delivery system in the treatment of skeletal disorders.[162]
In general, nonwoven and woven drug-loaded fibrous con-
structs are selected based on the final requirements of the
biomedical application. However, drug-eluting woven and knit-
ted fabrics provide more precise geometry, pore structure, and
strength than nonwoven fabrics. On the other hand, nonwoven
fabrics such as electrospun fibers with smaller pore sizes are
more feasible to reach nanostructures with sophisticated mor-
phologies. Nevertheless, considerable challenges must be solved
to scale up the fabrication procedure and to transform electro-
spinning into a commercial and operational process.[99,132] For
instance, the poor reproducibility, high dependency of process-
ing conditions on polymer-solution nature, and limitation of the
obtainable mesh thickness are the main challenges in aspect of
the mass production of nanofiber fabrics.[163]
4. Drug Loading of Fiber-Based Constructs
Drug-eluting systems provide sustained delivery of drugs and
other bioactive agents over a period of time from hours to
months. Drug-eluting fibers are recently used for delivering dif-
ferent kinds of drugs, such as antibiotics, anti-inflammatory
drugs, growth factors, anticancer drugs, proteins, DNA, gens,
and vaccines.[166,167] A variety of loading mechanisms are used to
produce drug-eluting fibers depending on the parameters such
as the type of drug, fiber production method, and the expected
drug release profile. For instance, the drug can be incorporated
at the prespinning stage by mixing with a polymer solution or
after spinning using methods such as coating and supercriti-
cal loading.[30,168,169] Coating,[170,171] encapsulation,[172,173] hollow
fiber filling,[174] ion exchange,[175–177] inclusion complex,[178,179]
direct conjugation,[180,181] hot-melt extrusion,[182] and supercrit-
ical impregnation [30,33] are some important methods that have
been used to load fibers with drugs through physical adsorption,
entrapment, and covalent attachment of the drugs to the fibers.[4]
4.1. Coating
Using this loading method, the drug is incorporated on the
surface of the fiber by immersing in a drug solution [171] or
by coating with drug encapsulated micro- or nanoparticles[183]
(Figure 5A). Several coating methods, such as electrochem-
ical deposition,[184,185] immersion,[170] dispersion, and curtain
coating[132] are used for drug incorporation onto the fibers. Coat-
ing parameters such as pH, solids content, and coating thick-
ness can be tuned to reach the desired coating.[132] In addition,
the bioactive components can be grafted to the coating material.
Therefore, the coating efficiency is depended on the type of the
material, the affinity of the drug to the fiber, coating thickness,
and the coating formula.[186]
One of the main issues in the controlled drug delivery sys-
tems is the initial burst release. There are some strategies ap-
plied to the coating procedure, which can help to achieve sus-
tained release over time, such as using microcapsules and adhe-
sives drugs that can adhere to biological tissues for an extended
period of time,[183,187] repeated layers of drug coating on fibers us-
ing L-B-L deposition,[188] or taking advantage of processes, such
as ultrasound, ion-beam, and irradiation.[4,28,189] For instance, Ma
et al.[183] coated cotton fabrics with a solution comprised of ta-
moxifen drug microencapsulated in gelatin B and acacia gum as
an anti-cancer drug for the treatment of breast cancer. Microcap-
sules remained on fabrics even after 5 and 10 cycles of washing.
The coating was stable, and the compound was released over 10
h after an initial bust release. The initial burst effect (30–60%,
1 h incubation time) was attributed to the fact that a significant
amount of tamoxifen was loaded in the vicinity of the microcap-
sule surface.
In addition, different structures of fibers can be formed us-
ing coating methods. For example, in a study by Zilberman,[190]
core–shell structures were created by coating the core polymers
of poly(l-lactic acid) (PLLA) for eluting hydrophilic horseradish
peroxidase and nylon for eluting hydrophobic paclitaxel. The
shell was made out of drug/protein-containing poly (dl-lactic-co-
glycolic acid) to form a porous shell structure. The fibers were
dip-coated in fresh emulsions of the shell material and subse-
quently freeze-dried. The structure and pore size of the shell was
tuned by organic:aqueous phase ratio, polymer concentration in
the organic phase, and the amount of drug. Both types of loaded
drug fibers had an initial burst effect followed by a reduction in
the release rate over time, normal for diffusion-controlled sys-
tems. In most of the samples, the horseradish peroxidase and
loaded PLLA fibers released 90% of the active agent over 90 d.
Paclitaxel exhibited a very low initial burst effect (less than 3%),
and over 30% of the drug was released within the first 30 days.
It was shown that a suitable formulation of the emulsion could
lead to a variety of new core-shell structures with favorable drug
release profiles.
Coating can also be used to protect the drug layer or as an
option for selective contact surface of the fibers with the target
area.[132] For instance, dispersion coating in which polymer dis-
persions are applied and dried on the surface to make a uni-
form and nonporous film can provide a protective layer for drugs
against possibly toxic substances by utilizing separate converting
machines or printing press. Also, the desired drug-coated surface
area can be obtained by sealing the unwanted sides.[99,132]
4.2. Encapsulation
In this method, incorporation of bioactive agents or drugs can be
done either before the fiber production (Figure 5B-I), by homoge-
neously mixing the polymer and the drug solution,[191] or during
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Figure 5. Schematic representation of drug loading methods onto the fiber-based constructs. A) Coating; incorporation of the drug on the surface of
the fiber. B) Encapsulation; incorporation of bioactive agents in the fiber matrix. C) Bioconjugation; coupling the bioactive agents to the surface of the
fiber in the presence of the functional groups. D) Inclusion complexes; accommodation of a small molecule (the guest, drug) in the cavity (the host,
drug carrier), where the complexes can be loaded on the surface of the fiber. E) Ion complexes; binding drugs to the surface of the fibers by using
contrasting charges to build ion complexes. F) Supercritical CO2 impregnation of aerogels; the mild temperature process can be also used to obtain
solvent residue-free drug-loaded fibers using CO2 above its critical coordination (31.1 °C, 73.8 bar).
the post fabrication process (Figure 5B-II), for example, by soak-
ing swellable fabrics in a drug solution.[79,192] Encapsulation of
drugs in the fibers is better performed in the preparation stage
as a higher dosage of drugs can be loaded.[173] Loading the fibers
through the pre-fabrication process depends on the solubility of
the drug and the polymer. However, it depends on the swelling
of the fiber and diffusion of the drug in the polymer matrix in
post fabrication.[4,11] In case of the low solubility of the drug or
the polymer in the solution, drug–polymer suspensions can be
prepared by dispersing fine drug particles followed by agitation
or exposing the drug-polymer solution to ultrasonic waves.[28]
Furthermore, the drug-eluting fiber can be made out of
suspension by electrospinning,[193] wet spinning,[194] or mi-
crofluidic spinning.[195–197] In wet spinning and microfluidic
spinning, encapsulation efficiency dramatically depends on the
type of antisolvent used to regenerate and solidify the fibers
as it might lead to partial dissolution of the drug.[106,194,195]
Wu et al.[198] fabricated microfibers made of polyacrylonitrile
(PAN) encapsulated with curcumin and vitamin E acetate.
The encapsulation at the solution preparation stage was suc-
cessful and both drugs were loaded; however, the actual drug
loading content was lower than the theoretical drug loading
content due to the diffusion of the drugs into the coagulation
bath. The drug-loaded filaments showed a microvoid structure
caused by entrapment of solvent and non-solvent molecules
and subsequent drying of the fibers. The pores could enhance
the specific surface area, air permeability, and the drug re-
lease rate. Woven textiles from PAN filaments showed good
cytocompatibility with prolonged drug release profile over more
than 600 h.
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4.3. Bioconjugation
In this approach, to couple the bioactive agents to the surface
of the fiber, the presence of the functional groups, such as
carboxyl,[199] amine,[200] and sulfonic groups,[201] on fibers are re-
quired. Surface functionalization can be performed using plasma
treatment, wet chemical method, grafting, and co-spinning.
When the surface is functionalized, drugs can be coupled to the
surface of the fiber by, for instance, chemical conjugation, such as
covalent, or physical conjugation, such as adsorption.[180,181,201,202]
4.3.1. Plasma Treatment
In this method, surface adhesion and hydrophobic or hydrophilic
properties can be tuned by altering the surface chemical struc-
ture. Furthermore, various functional groups, such as carboxyl
and amine, depending on the gas used to create plasma, can
be added to the surface (Figure 5C-I). Fiber surfaces with acti-
vated functional groups created by plasma treatment have been
used to couple with protein-based materials, such as gelatin, col-
lagen, laminin, and fibronectin, to enhance cellular adhesion and
proliferation.[192,203,204]
4.3.2. Wet Chemical Method
Plasma treatment is limited to the surface area, whereas wet
chemical methods, such as partial surface hydrolysis, can be
a solution to increase the conjugation sites.[205,206] This means
that the surficial ester linkages in the polymer chain backbones
of biodegradable aliphatic polyesters under acidic or basic
conditions will be chemically cleaved; therefore, carboxylic and
hydroxyl groups will be generated while the polymer remains
water-insoluble.[180] Sun et al.[207] investigated simple alkali
hydrolysis as an efficient way to modify polyesters, such as PCL,
to couple a cell-recognizing peptide to a carboxylated surface.
4.3.3. Graft Copolymerization
Another approach to conjugate drug molecules on the fiber sur-
face through chemically or radiation-induced graft polymeriza-
tion is graft copolymerization (Figure 5C-II).[180,208] Using this
method, multifunctional groups, hydrophobic or hydrophilic,
can be tailored.[180] In a research done by Park et al.,[209]
poly(glycolic acid) (PGA), PLLA, and poly (lactic-co-glycolic acid)
(PLGA) electrospun fibers were functionalized using oxygen
plasma treatment, and in situ grafting of hydrophilic acrylic acid
(AA) to incorporate hydrophilic functional groups resulted in bet-
ter fibroblast proliferation.
4.3.4. Co-spinning
In this approach, it is essential to achieve a homogenous polymer
blend solution of nanofibers, nanoparticles, and functional poly-
mer segments prior to spinning.[4,180] Functional groups can be
located on the fiber surface via co-spinning of different polymers
containing various functionalities (Figure 5C-III). For example,
Sun et al.[210] fabricated antibacterial surface-biofunctionalized
electrospun PEO fibers as a host polymer and an oligopeptide
conjugate. This was a single-step method to obtain surface bio-
functionalized fibers, which possess three repeated units of a
triad serine, glutamic acid, and glutamic acid (Ser-Glu-Glu)3 us-
ing the co-spinning method.
4.4. Inclusion Complexes
An inclusion complex is a compound in which a small molecule
(the guest) can be accommodated in its cavity (the host) (Fig-
ure 5D). Usually, inclusion complexes are referred to as tex-
tile slow-release systems due to their ability to release the guest
compound in a slow and continuous manner.[4,132,211] Several
large molecules such as CD, fullerene, azacrown ether, and their
derivatives can be used to produce inclusion complexes.[212,213]
The most well-known inclusion compound used in drug-
releasing textiles is CD, cyclic alpha-1,4 linked oligosaccharides
consist of numerous d-glucose units, alpha-, beta-, and gamma.
The hydrophilic interior and hydrophobic exterior of CDs make
them favorable substances in the complexation of drugs.[213–215]
The first step in loading fibers is to introduce cyclodextrin
on the surface of fibers which can be achieved by using one
of the bioconjugations explained in Section 4.3.[178,179] Then,
the surface of the fibers is ready to form inclusion complexes
with bioactive agents for drug delivery purposes (Figure 5D).[211]
As an example of using CD, wool fibers grafted with 𝛽-CD
using low-temperature oxygen plasma treatment and dyed with
antibacterial natural colorant berberine[178] or polyamide fibers
coated with a CD–ciprofloxacin[179] proved to have significant
antibacterial activity.
Furthermore, CDs can be introduced into the fiber during fiber
fabrication. For example, CDs entrapment within the fibers was
achieved by melt spinning using materials such as polyesters and
polyamides. It was shown that instant cooling of the fiber ex-
iting from the spinneret forced CDs to migrate to the surface
of the fiber and thus made them accessible to form complexes
with drugs. This migration occurred due to hydrophilic external
surface of the CD which blocked complete perforation into the
fiber.[216,217] In another research, Yildiz et al.[218] studied the po-
tential of co-spinning conjugated polymer and drug solution to
fabricate self-standing and quick-dissolving fibrous textiles from
carvacrol/CD inclusion complexes. The result enhanced the hy-
drosolubility, thermal stability, and antioxidant activity of the fi-
brous web, which can have a potential to be used for food and
oral care applications.
4.5. Ion Complexes
Drugs can bind to the surface of the fibers by using contrasting
charges in order to build ion complexes. Drug release is then
relying on the external solution or the ability of the fiber surface
to preferentially exchange counter-ions that are influenced by
the type and the concentration of the surface ion-exchange
groups (Figure 5E).[4,27,99,132] Ion complexes undergo a stoi-
chiometric exchange reaction and can have extensive exchange
Macromol. Biosci. 2021, 2100021 2100021 (12 of 31) © 2021 The Authors. Macromolecular Bioscience published by Wiley-VCH GmbH
www.advancedsciencenews.com www.mbs-journal.de
potential, making them a suitable candidate as a multiple drug
carrier.[35,176,177] In a study by Liao et al.,[175] fibers from a blend
of chitosan-alginate with charged surfaces were produced. Drug
complexation was created with several bioactive charges includ-
ing dexamethasone, BSA, growth factor (PDGF-bb), and avidin
mixed with either chitosan or alginate solution. Electrostatic
interaction among the charged fiber and the charged drugs
controlled their release mechanism and profile from the fibers;
therefore, the elution time of the components from these fibers
ranged from hours to weeks.
In another study, Gao et al.[219] investigated the drug release
from the poly(propylene-g-styrene sulphonic acid) fibers loaded
with tramadol hydrochloride as a model drug. The tramadol
was consistently delivered from the drug-loaded fiber when
iontophoretic, a noninvasive technique to increase transdermal
penetration using a voltage gradient, was applied since com-
bining ion-exchange fiber with iontophoresis will decrease the
fluctuation of the drug release.[220] Some commercially available
ion-exchange fibers are the Smopex fibers, which contain
polyethylene backbone grafted with other polymers such as
polystyrene sulphonic acid (Smopex-101), polyacrylic acid
(Smopex-102),[221] or polyamide (Smopex-108).[176] In short,
ion-exchange fibers have demonstrated great abilities to release
various ionic drugs loaded into ion-exchange groups. These
functional fibers can be ultimately used to produce woven or
nonwoven fabrics.
4.6. Supercritical CO2 Impregnation
Supercritical impregnation is a mild temperature process to load
fibers with bioactive agents, providing a drug-loaded textile free
of any solvent residue. CO2 above its critical temperature and
pressure, 31.1 °C and 73.8 bar, respectively, is in the supercritical
state. The critical temperature of CO2 is relatively low and easily
achievable, making it a mild solvent for temperature-sensitive
materials. Supercritical CO2 (scCO2) is a “tunable solvent” as
its properties, such as viscosity, density, and diffusivity, can
be controlled by varying pressure or temperature.[15,30,222,223]
Furthermore, scCO2 has an intermediate behavior between gas
and liquid, possessing a density similar to that of the liquid,
0.2–1.5 g cm−3, and transport properties close to those of the
gas. In addition, scCO2 is a dissolvable medium for nonpolar
low molecular weight compounds; however, in case of poor sol-
ubility, a cosolvent like ethanol is used to increase the solubility
of the polar molecules.[30,224]
In biomedical applications, temperature and pressure range
between 35 and 55 °C and 90–200 bar have been investigated
for drug loading.[30,225] This method has been mainly used in
producing and loading aerogel. However, due to the low me-
chanical properties of aerogels in fibers, they have not been ex-
tensively investigated.[223,226] Drug loading in the aerogel fibers
can be done either during gel preparation (Figure 5F-I), during
the conventional sol-gel process, so-called solvent exchange (Fig-
ure 5F-II), [227] or during the post treatment of the synthesized gel
(Figure 5F-III).[228] Post treatment loading has been extensively
utilized for nonaerogel materials too.[225,228] The post treatment
loading process consists of three main steps. At first, the solute
is dissolved in the scCO2 and then the polymer is exposed to the
solution of scCO2, where the bioactive agents and the solution
diffuses into the polymer bulk. The loading efficiency is depen-
dent on the CO2 ability to swell the polymer matrix.
Finally, the last step is depressurization, in which CO2
and non-impregnated drugs are removed from the loading
chamber.[229,230] The drug loading efficiency in this method de-
pends on the solubility of the drug in CO2, CO2 sorption, polymer
swelling, the affinity of the drugs to the polymer, and the pro-
cessing factors, such as pressure, temperature, loading time, dif-
fusion process, and depressurization conditions.[30,230–232] Some
example of loaded textiles are cellulose acetate (CA) fibers im-
pregnated with menthol and vanillin,[222] chitosan with dexam-
ethasone as a scaffold for bone tissue engineering,[233] and colla-
gen and cellulose as a commercial wound dressing (Promogran)
impregnated with anti-inflammatory jucá (Libidibia ferrea).[234]
Using the supercritical impregnation method, fibers with
different geometries can be loaded using hydrophilic or hy-
drophobic drugs. For instance, a dual-drug solvent exchange
impregnation into core–shell electrospun nanofibers was
achieved by scCO2 method.
[235] The scCO2 was able to load the
model BODIPY 493/503, as a hydrophobic model drug, into the
hydrophobic PCL core and impregnation of the rhodamine B, as
a hydrophilic model drug, into the hydrophilic shell. Hydropho-
bic or hydrophilic drug-polymer interactions improved the drug
loading and caused a steady linear release. Since scCO2 localized
the drugs throughout the entire fiber matrix, scCO2 drug-loaded
fibers demonstrated a controlled and extended bimodal release
compared to immersed fibers in a solution containing the two
drugs. Therefore, scCO2 can be used as a tunable medium for
loading various drugs into a fibrous structure.
Selecting a suitable drug impregnation method is crucial in the
final properties of the fibrous delivery system. Therefore, several
factors should be considered in the selection process including
material or production cost, biostability, biodegradability, toxic-
ity, ex vivo or in vivo drug delivery, and their compatibility with
the fiber/textile production. For instance, in the case of inclusion
complexes, known for creating slow-release systems, modified
cyclodextrins costs are high; also their final fixation on the tex-
tile surface is required since high dosage release of cyclodextrins
can be toxic.[32,48] The fiber spinning condition, final morphol-
ogy, and drug loading capacity are other factors that can limit the
choice of impregnation method. Nevertheless, conventional fiber
and drug loading production techniques such as coating and in-
corporating the drugs into the polymer or melt solution are yet
favorable due to their simplicity.
5. Characterization of Drug-Eluting Textiles
Several methods are used to characterize drug-releasing textiles;
however, the most common methods are those that determine
the chemical functionality, biological activity, surface morphol-
ogy, mechanical properties, durability and degradation, and drug-
loading and release kinetics. Infrared (IR) spectroscopy is widely
used in identifying the chemical functionalities of fiber surfaces.
Most chemical functionalities absorb infrared frequencies that
correspond to their molecular vibrational frequencies. IR can
detect the majority of the mobilized compounds on the textile
surfaces. In addition, any changes to the surface morphology
of the textiles can be detected by scanning electron microscopy
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(SEM).[236] The surface analysis can also give an idea about the
durability and surface degradation, which indirectly refers to the
release behavior of the drug-eluting textiles.[237] For the degrada-
tion studies, simulated body fluids at physiological temperature
are used. Enzymes can be added to the testing medium to accel-
erate the degradation of the base textiles.[238]
Determining the biological activities of the medical textiles,
especially, antibacterial properties is essential when antibiotics
are incorporated. AATCC 100 and 147 are widely used in the an-
timicrobial assessment of textile fabrics. In addition, evaluation
of the physical and mechanical properties of the drug-eluting
systems is essential in order to determine their suitability for
different applications.[239] Finally, understanding the release be-
havior of the drugs is crucial to satisfy the requirement of the
final application. Different mechanisms of drug release from
fiber-based constructs are thoroughly discussed in the following
sections.
5.1. Drug Release Mechanisms
Textile-based drug release systems should be able to deliver the
drugs efficiently, accurately, and for a defined timeframe. The
term “release mechanism” illustrates the procedure in which
drugs are transported or released.[132] In textile-based systems,
regulation of the drug release rate is dependent on parameters
such as geometry (size and shape), morphology, and material
properties, such as swelling and degradation, of the carriers or
host molecules.[27,99,132]
The most addressed drug release mechanisms are immediate,
extended, and triggered or delayed release.[27,132,240] As shown in
Figure 6A-I, in the immediate release, there is a rapid release
of the drugs in a short time. However, in extended release
(Figure 6A-II), the drug is delivered at a lower rate constantly
or variably over an extended period of time. Finally, in triggered
release (Figure 6A-III), different stimuli, such as pH or temper-
ature, initiate the release procedure, which can be immediate or
extended.[27,132]
5.1.1. Immediate Release
In some circumstances, where an instant reaction is necessary,
immediate drug release is preferred. For example, a rapid release
rate of antibiotics in the first hours following the biomaterial
implantation is vital to avoid implant-related infection.[241,242] He
et al.[243] spun a fibrous structure blend using electrospinning
to incorporate a model drug TC.HCl into PLLA fibers. The
nanofibers from the TC.HCl /PLLA blend showed an imme-
diate release and prevented bacterial infection. Johnson et al.
investigated the release of a hydrophobic model drug, Nile Red,
from the emulsion electrospun fibers containing PCL (oil) and
nonionic surfactant, Span 80. The samples with and without
surfactant exhibited an initial burst release continued by a slower
continuous drug release over one hour. However, the burst re-
lease of the model drug from nanofibers with surfactant was
lower, due to the interaction of the model drug at the interface
of emulsion and the fiber body and the lower surface area of
samples with the surfactant.[244]
Figure 6. Drug release mechanisms. A) Most common examples of drug
release mechanisms, immediate, extended, and triggered or delayed-
release. B) SEM (x,y,z) and TEM (w,v,u) images of PLLA fibers co-
electrospun with (x,w) DOX, (y,v) MSN-DOX, and (z, u) MSN-DOX-
CaCO3. EDX spectra of x’) PLLA-DOX, y’) PLLA-MSN-DOX, and z’) PLLA-
MSN-DOX-CaCO3. C) Drug release profiles of I) PLLA and II) PLLA-MSN-
DOX-CaCO3 at various pH conditions. III) Schematic explanation of drug
release mechanism of electrospun fibers. The interaction of protons (H+)
from the acidic media diffusion into the nanofibers; protons react with the
CaCO3 channel gates of MSN to release the encapsulated DOX inside the
mesoporous structure and produce CO2 gas, causing water penetration
into the PLLA fibers and accelerating the DOX release. B,C) Reproduced
with permission.[247] Copyright 2015, Elsevier.
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5.1.2. Extended Release
In extended release systems, the drug is released at a constant or
variable slow rate over an extended time.[99,132] In this system, dif-
ferent phenomena such as diffusion,[33] decomplexation,[178] ion
exchange,[177] dissolution, erosion, swelling, and degradation[245]
can control the release rate.[246] In systems such as fibers loaded
with encapsulated drugs[173] or hollow fibers,[92] the main mech-
anism of the release is based on the diffusion; therefore, the
concentration gradient and diffusion coefficient govern the re-
lease rate. The release rate of inclusion complexes is controlled
by kc and kd, the complexation and decomplexation constants,
respectively,[214] and is usually depended on the interactiveness
of drug as the guest molecule and host molecule.
In some cases, the release rate is regulated by the dissolu-
tion rate of the macromolecular structure in which the drug is
loaded. Examples of such systems are fibers loaded with encap-
sulated drugs in which the matrix is soluble in the surrounding
media. Some drugs can bind to ion-exchange materials as ex-
plained in Section 4.5. In ion-exchange textile systems, the elut-
ing rate of the bioactive compounds attached to ion-exchange
fibers is controlled by the ability of the textile surface to prefer-
entially exchange counter-ions, the concentration of the surface
ion-exchange groups, the ionic characteristics or the pH of the
local medium, and the type of the ion-exchange material. In addi-
tion, erosion and degradation governed structures benefit from
a biodegradable macromolecule that is gradually eroded or de-
graded and as a result, drugs are eluted.
The fiber erosion or degradation rate regulates the release
rate of the drugs.[246] However, dissolution, ion-exchange, ero-
sion, and degradation can be the mechanism behind triggered
or delayed release too.[27,132] Volokhova et al. irradiated electron
beam on paracetamol-loaded PCL electrospun meshes covered
with pure PCL nanofibers. The combination of e-beam irradia-
tion and the fibrous layer resulted in an extended release profile
with no burst effect and enhanced drug release quantities over
time since e-beam reduced the PCL molecular weight and the
multilayers created diffusion barrier and declined swelling.[83]
5.1.3. Triggered or Delayed Release
A trigger/stimulus or time can determine the release of the drug
in these systems. Therefore, the type of release can be immedi-
ate or extended based on the material and design. The release
can be triggered by stimuli such as light, pH, temperature, ionic
strength, sonification, erosion, degradation, and dissolution.
Therefore, consecutive release profiles over a longer period can
be achieved.[27,132] Zhao et al.[247] fabricated a smart and tumor
pH-trigged PLLA electrospun fabric for inhibiting cancer relapse.
Mesoporous silica nanoparticles (MSNs) were loaded to the fi-
brous structure to extend the anticancer drug doxorubicin (DOX)
release, which was physically adsorbed onto MSNs. CaCO3 inor-
ganic caps were incorporated to temporarily block the pores of
MSN loaded nanofibers until the pH change triggered the drug
release. CaCO3 caps were stable at physiological pH of 7.4; how-
ever, in an acidic media where protons were released from the
tumor cells (pH < 6.8), CaCO3 gates dissolved into biocompati-
ble Ca2+ (cations) and released CO2 gas. This phenomenon led
to increased water penetration into the PLLA nanofibers and ac-
celerated DOX release. This pH-dependent drug-loaded fibrous
system can inhibit long-term exposure of drugs to healthy cells
by preventing drug release at non-acidic conditions.
In this study, three main groups of PLLA fibers co-electrospun
with DOX (Figure 6B-x,w,x’), MSN-DOX (Figure 6B-y,v,y’), and
MSN-DOX-CaCO3 (Figure 6B-z,u,z’) were fabricated, and SEM,
transmission electron microscopy (TEM), and energy-dispersive
X-ray (EDX) were used to analyze the morphology of fibrous
structures and the effect of drug loading on the fiber structure.
Comparing the release profiles of DOX loaded fibers (Figure 6C-
I) with the electrospun CaCO3 caped fibers (Figure 6C-II) at var-
ious pHs demonstrated significant pH-dependent drug-eluting
behavior. Moreover, sustained drug release over a period of 40 d
from MSN-DOX-CaCO3 fibers was observed only when the en-
vironment became acidic (Figure 6C-III). Finally, this example
showed the importance of the triggered release in providing a
sustained drug release while minimizing the damage to untar-
geted tissues.
5.2. Kinetics of Drug Release
The drug release kinetics from fiber-based structures is influ-
enced by various mechanisms, vigorously relying on polymer–
drug system properties and interactions, such as physicochem-
ical characteristics of the drug, fiber spinning and loading
methods, the solubility of the drug in the release medium, and
the interactions between the loaded material and the target
tissue.[4] Various mass transport mechanisms, including diffu-
sion, swelling, dissolution, erosion, or a combination of them
governs the drug extraction from a polymer matrix. Generally, hy-
drophilic drug release occurs through simple diffusion, whereas
water-insoluble drugs release happens by swelling or erosion of
the macromolecule matrix.[248] Mathematical models have been
proposed to describe, quantify, and predict the kinetics of drug
release. Therefore, fitting experimental data of drug release with
various mathematical models is a key to understanding how the
polymer–drug systems affect the transport mechanisms to tune
therapeutic parameters, such as the drug dose, release rate, and
the release time.








As dC/dt is the dissolving rate, D the diffusion coefficient of
the drug, h the width of diffusion path, A the surface area of
the subjected polymer to medium, Cs the saturated amount of
dissolvable drug, and C(t) the drug concentration in the release
medium at time t.
The drug release profile can be obtained by plotting the drug





Q(t) is the cumulative fraction, Mt is the amount of drug at time
t, and Mtot is the total amount of loaded drug.
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Figure 7. Representation of the release kinetics models. A) Evaluation process of experimental drug release data with empirical models. B) linearized
plots of most common release model drugs, I) Zero-order model, II) First-order model, III) Higuchi simplified model, IV) Hixon-Crowell model, V)
Korsmeyer-Peppas (power-law model), and VI) Peppas-Sahlin, variation of the Fickian diffusional exponent, m, with the aspect ratio, 2a/l, where 2a is
the diameter (width) and I is the thickness (height) of the matrix. Reproduced with permission.[42] Copyright 2015, Elsevier.
The release profiles of each polymer–drug system can be
assessed and explained by a mathematical model. The statis-
tical coefficients, namely the higher coefficient of determina-
tion (R²) and the lower AIC (Akaike Information Criterion),
are used to check the accuracy of the model to justify the ex-
perimental data. Therefore, the mechanisms with the highest
potential to control the drug release can be recognized from
the best fit model (Figure 7A). Several common mathematical
models applicable for macromolecule systems, zero-order, first-
order, Higuchi, Korsmeyer-Peppas, Hixson-Crowell, and Peppas-
Sahlin, are reviewed in the following sections with an emphasis
on drug-eluting fibers.
5.2.1. Zero-Order Model
Zero-order kinetics is an “ideal” linear drug release profile. The
eluting rate is independent of the drug concentration in the sys-
tem and remains constant over time.[249,250] This model can be
explained by:
Q(t) = k0tn (3)
where Q(t) is the cumulative fraction of the drug released at the
time t, k0 is the constant rate or apparent dissolution rate, and n
is geometrically dependent, 1.0 for a thin film, 0.89 for a cylinder,
and 0.85 for a sphere. In some studies, the researchers have con-
sidered electrospun meshes as thin films, while for single micro-
fibers, the cylinder geometry seems to be more accurate.
A graphical representation of the model is shown in Figure 7B-
I. Zero-order release typically happens in transdermal or osmotic
systems and for prolonged-release from a system that does not
break down when loaded with a very low soluble drug. Ahadi and
co-workers[251] fabricated electrospun vancomycin hydrochloride
(vanco HCL) loaded PLLA fibers. The electrospun fibers were
added to a silk fibroin/oxidized pectin hydrogel as a secondary
structure where drug-loaded hydrogel/fiber complexes were fab-
ricated. During the first day (24 h), the release amount of vanco
HCl from drug-loaded hydrogel was 35.97% while from hydro-
gel/fiber composite was 13.83%. The drug release mechanism in
such a gel-fiber system can be complicated and affected by pa-
rameters such as polymer degradation, hydrogel swelling, and
hydrophobicity or hydrophilicity of the fibers. In order to eval-
uate the kinetics model, maximum linearity was considered to
check the accuracy of the model. The drug-loaded hydrogel/fiber
proved to have zero-order release with K0 = 3.307 and R2 = 0.98.
5.2.2. First-Order Model
First-order release kinetics is corresponding to the amount of
the loaded drug in the matrix. This model results in constant
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release overtime, and the rate is only dependent on the initial
drug concentration.[252] The cumulative released fraction can be
described by:













where (1 - Q(t)) indicates the residual fraction of drug at the time
t in the system, and k1 is the first-order constant (Figure 7B-II).
The first-order kinetics is favorable for the sustained release of
the drug delivery systems. For example, it can be observed in sys-
tems consisted of water-soluble drugs loaded in a porous matrix,
where the release rate is only controlled by diffusion or dissolu-
tion.
Painuly et al.[172] studied a drug delivery system based on
gelatin nanofibers for two contraceptive drugs comprising lev-
onorgestrel (LNG) and ethinylestradiol (EE). In the case of indi-
vidual loading of the drugs, it was observed that the release of EE
was altered by the initial content of the loaded drug, whereas no
significant difference was seen for the LNG with a sustained re-
lease of 30–35 µg day–1. This could be attributed to the hydropho-
bic nature of LNG as no significant difference in morphology of
the loaded fibers with increasing the LNG dosage was observed.
On the other hand, fibers loaded with both LNG and EE showed
a minor burst release on the first day, followed by a sustained
release of both drugs up to 7 d.
In addition, LNG release was ≈4–5 fold increased in dual drug-
loaded samples compared to single LNG loaded fibers due to the
combination of drugs. In vitro LNG release kinetics could be fit-
ted by zero-order and first-order model with R2 ≥ 0.99 for both
models. EE/gelatin nanofibers were described convincingly by
zero- and first-order models with R2 in the range of 0.93–0.97. In
the case of dual drug loading, the release of LNG and EE was de-
scribed by zero-order and first-order model for LNG (R2 ≥ 0.99),
whereas Higuchi and Korsmeyer-Peppas model, explained in the
following section, could better describe the EE release (n = 0.49,
R2 ≥ 0.97).
5.2.3. Higuchi Model
There was no mathematical model to explain the drug dissolution
from matrix systems until the 1960s. One of the earliest models
has been described by Higuchi[253] which was initially effective
only for a planar matrix but later was adjusted to be applied to
different geometries and matrices.[254] Higuchi model is based on
Fick law and describes the release kinetics of a hydrosoluble drug
dispersed in a homogeneous solid matrix. Drug release happens
by Fickian diffusion of the release medium and the drug within
the pores macromolecule structure. The model is justifiable if
the diffusion coefficient or matrix geometrical dimensions of the
matrix are persistent over time,[253] meaning that it does not apply
to cases such as swellable or soluble delivery systems.










where 𝜖 is the polymer porosity, 𝜏 is the capillary tortuosity factor,
md is the initial amount of the drug, and Sd is the solubility of
the drug. Tortuosity is used to describe diffusion and fluid flow
in porous media and it is the proportion of radius and branching
of the pores and canals in the matrix.




where KH is the release constant of the Higuchi model. As ex-
pected from Fick’s law, the amount of released drug is propor-
tional to the square root of time. A graphical representation of
the model is shown in Figure 7B-III.
In a study by Pisani et al.,[255] gentamicin sulfate (GS) was en-
capsulated into polylactide-co-polycaprolactone (PLA-PCL) elec-
trospun nanofibers. Due to the antibacterial activity of the GS-
loaded fibrous meshes, they were used for the topical controlled
drug delivery for treating infected skin and gum or for preventing
infection in bone surgery. The kinetic release of the drug-loaded
fibers could be predicted and explained by the Higuchi kinetic
model, both in dynamic and static conditions (R2 ≥ 0.9).
5.2.4. Hixson-Crowell Model
The Hixson-Crowell model is based on two assumptions; drug
release is limited only by drug dissolution rate, and the matrix
erosion happens by decreasing the dimension of the matrix while






Mt = kHCt (7)
where M0 is the initial amount of the drug in the system. The re-
maining drug in the system at time t is Mt, and kHC is the constant
of incorporation, which connects the surface and the volume of
the drug.






= 1 − k𝛽 t (8)
where (1-Q(t)) is the remaining fraction of drug within the poly-
mer matrix, and k𝛽 is a release constant (Figure 7B-IV).
Hixson-Crowell model could satisfactorily represent the re-
lease kinetics of curcumin (CUR) loaded in zein (zein-CUR) elec-
trospun fibers, where the morphology and the size of fibers were
strongly dependent on CUR loading dosage. This was mainly due
to the hydrogen bonding between CUR and the fibers and a slight
increase in the Tg of the zein matrix. In the case of 20% w/w CUR
loading, around 70% of the drug was released in 180 min. Fur-
thermore, a higher dosage loading caused a faster release rate due
to the diffusion-controlled release behavior of the system which
was derived from CUR dosage change.
By investigating several models for three different CUR load-
ing dosages, the first-order model exhibited the highest value of
R2 (0.9940–0.9969), indicating that the CUR diffusion in fibers
might be a rate-limiting step. Furthermore, the release profile
was explained by Hixson–Crowell model with a relatively high
R2 (0.9638–0.9896), which additionally clarified that the CUR re-
lease from the fibers was mainly based on the diffusion rather
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than the matrix erosion mechanism. Finally, the system was eval-
uated for antibacterial activities using Escherichia coli and Staphy-
lococcus aureus bacteria. The outcomes showed good antibacterial
activity toward the targeted bacteria where the bacterial inhibition
capability improved with the increased CUR contents.[257]
5.2.5. Korsmeyer–Peppas Model
The Korsenmeyer-Peppas, as a semiempirical model, explains
the exponential relationship between the release and the time.
It is mainly used to inspect the release of the drug from a hy-






where Kkp is the constant accounting for the dimensional prop-
erties of the system, also assessed as the release rate constant,
and n is the exponent of release related to the drug release mech-
anism as shown in Figure 7B-V. This model can be used when
the release mechanism is unknown or when more than a known
mechanism is involved. The dominant physical mechanism of
drug release is recognized by obtaining the value of the exponent
n based on the optimal fit with experimental data (for (t) < 60%)
and the system dimension.
Fickian diffusion or non-Fickian mechanisms alter with the
rate of solvent diffusion. In the case of n = 0.45 or Fickian dif-
fusion, the typical molecular diffusion of the drug occurs due
to a chemical potential gradient. In other words, the rate of sol-
vent diffusion is much slower than polymer relaxation (swelling
or/and erosion of matrix) time. This case is similar to the model
described by Higuchi for Fickian diffusion. However, in non-
Fickian mechanisms, when 0.45 < n < 0.89, the release is con-
trolled by both diffusion and macromolecule relaxation (swelling
or erosion) since solvent diffusion and polymer relaxation occur
at comparable time rates. When n = 0.89, the mechanism is gov-
erned by polymer relaxation, which is similar to zero-order kinet-
ics. Finally, in the case of n > 0.89, an extreme form of transport,
called non-Fickian diffusion, driven by the acceleration of solvent
penetration occurs.
Generally, these models have been used to study drug deliv-
ery from sources such as tablets, hydrogels, membranes, and
fibers. The water molecules in majority of the studied systems are
the initiators of the drug release process through swelling of the
loaded polymer matrix.[260,261] Furthermore, the rate-restricting
phenomena for a hydrophilic drug loaded in water-insoluble and
non-erodible fibrous structure, such as CA nanofibers, is diffu-
sion through typically a hydrophobic hindrance.[262]
For instance, gallic acid (GA) was microencapsulated in
PCL by the solvent vaporization, and the homogenous PCL–
microspheres were applied onto textile substrates of cotton and
polyamide. GA has shown biological activities, including antiox-
idant, antityrosinase, antimicrobial, anti-inflammatory, and anti-
cancer properties.[261] The apparent diffusivity, D, was obtained
using the Fick’s second law, Higuchi model (Equation 6). The ki-
netic studies done using Korsenmeyer-Peppas equation proved
that the hydrophobicity and affinity of the textiles and GA affected
the eluting mechanism. The apparent diffusion coefficients were
predicated for plane surfaces. For cotton, an explicit Fickian dif-
fusion was obtained (n ≈ 046, n ≤ 0.5); however, for polyamide,
the diffusion was anomalous (n ≈ 0.63, 0.5< n< 1). Moreover,
no differences were found in the Kkp (Equation 12), which is the
constant comprising the dimensional properties of the system.
5.2.6. Peppas-Sahlin
Peppas-Sahlin is a power-law model originated from
Korsenmeyer-Peppas (Equation 12) which take into account
the role of two physical mechanisms: diffusion and macro-




= KFtm + KRt2m = F + R (10)
where KF is the diffusion constant, KR the relaxation constant,
and m is the Fickian diffusion exponent of a matrix of any di-
mensional shape (cylinders, tablets, and films).
The model assumes that drug is eluted from any matrix, disre-
garding of its dimensional structure shape, consists of a Fickian
and a relaxation term. If the Fickian character can be stated as a
function of tm, the polymer relaxation role can be indicated as a
function of t2m. The Fickian diffusional exponent, m, differs with
the ratio between the width and height of the matrix in which
Peppas and Sahlin defined it as 2a/l, where 2a is the width (di-
ameter) and l is the height (thickness) (Figure 7B-VI). The drug













PLA/ polyvinyl alcohol (PVA) core–shell nanofiber scaffolds
loaded with BMP-2 proteins to enhance the recovery of alveo-
lar bone tissue were used in a study. Albumin was utilized as a
model drug to optimize the fiber production and loading parame-
ters. Fabricated core–shell nanofibers released 30% of the loaded
albumin while PVA monolithic fibers released 92% of the encap-
sulated albumin in 1 h. Peppas-Sahlin could sufficiently explain
the release of albumin (R2 > 0.98, m = 0.45), suggesting that the
albumin release occurred through the Fickian diffusion process.
Based on the in vitro results, cell viability, adhesion, and prolifer-
ation were observed.[264]
Other models such as Hopfenberg,[265] Gallagher–
Corrigan,[266] Weibull,[267] have been also utilized in different
research studies to predict the drug release from various drug-
loaded materials. In summary, these models are valuable tools
to discover the exact mass transport and quantitative estimation
of drug release. Using these models, scientists are able to design
a controlled and tunable release from drug-eluting systems in
various applications. Examples of the applications that have used
the drug-eluting systems are reviewed in the next section.
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6. Applications
A wide spectrum of drug-loaded textiles has been designed to
deliver various bioactive agents in various manners. Numerous
manufacturing processes alongside the loading methods of var-
ious pharmaceutical agents have made the drug-eluting fibrous
system an interesting candidate for three main application areas
of wound care, tissue engineering, and transdermal drug delivery
system (Figure 8A).
6.1. Wound Care
An ideal wound dressing has characteristics such as oxygen and
water vapor permeability, resistance to the penetration of mi-
croorganisms, and antimicrobial activity to prevent infection.
Furthermore, it should be easy and comfortable to apply to the
wound, minimize the pain, and inhibit bleeding.[132,268] The deliv-
ery of bioactive agents has a significant role in the wound-healing
process. This includes a wide range of compounds and measures
including antimicrobials to avoid or heal infection, growth factors
to help cellular proliferation, cleansing or debriding agents for
eliminating necrotic tissue.[4] The biomaterials used for wound
dressing should also be biocompatible and assist the growth of
skin cells. Woven and nonwoven textiles that have small pore
sizes to permit controlled fluid transport and resist the infiltra-
tion of infectious microorganisms can be sued for this appli-
cation. Moreover, both degradable and nondegradable materials
have been used for the production of wound dressings.[4,132]
Degradable polymers are suitable candidates to be used as skin
scaffolds, whereas nondegradable polymers can be employed as
temporary wound dressings.[269] As an example, polyurethane
(PU), as a nondegradable polymer, has been used for wound
dressing application due to its elastic properties.[270] However,
it is also possible to synthesis PU in a degradable form, such
as poly(ester-urethane) urea (PEUU), which could be used as a
scaffold for skin tissue engineering.[271] If an individual material
cannot satisfy the requirements of the application, a combina-
tion of various materials, such as degradable and nondegradable,
can enhance the firmness, spinnability, strength, wettability, and
bioactivity of the fibrous system.
Medical device-related infections and antibiotic-resistant
issues require anti-infective materials to preserve wounds and
medical devices.[272] In this direction, utilization of chitosan
as a base material for antimicrobial wound dressings was
explored. A tricomponent antimicrobial nanofiber composite
from chitosan/polyvinyl alcohol/silver nanoparticles was devel-
oped via electrospinning,[273] where green chemistry principles
were applied. Chitosan was employed as a capping agent and
glucose as a reducing agent for silver nanoparticles (25 nm
diameter). Nanofibers with 150 nm average diameter of regular
cylindrical shape morphology were obtained upon blending
chitosan/ silver nanoparticles with PVA and cross-linking with
glutaraldehyde. The release profile of silver ions from nanofiber
mats was assessed by atomic absorption. The nanofiber mats
attained sustainable release behavior over 7 d and exhibited
high antibacterial activity against E. coli at low silver nanopar-
ticle loads. In another study, the chemical modification of
chitosan using iodoacetic acid was evaluated, where 1-ethyl-
3(3-dimethylamminopropyl) carbondiimide hydrochloride with
hydrochloric acid (EDAC·HCl) and N-hydroxysuccinimide
(NHS) coupling was employed.[274] The chitosan iodoacetamide
derivative exhibited bactericidal properties when tested against
E. coli. It is thought that the incorporation of iodine active
terminal into a chitosan backbone resulted in an increase in the
antibacterial effectiveness by disulfide bond development with
the proteins of the bacterial outer membrane.
Electrospun mats were made out of gelatin and incorporated
with polyhydroxy antibiotics. These antibacterial drugs have a
various number of hydroxyl groups in order to make strong
interfacial bonds to gelatin by the aid of in situ crosslinking with
polydopamine (pDA). Vancomycin (Van) loaded fibers showed
to have high mechanical properties and to modulate cytokine
production essential in stopping sepsis after burn injury.[275] The
direct electrospinning of Van-loaded gelatin on cotton gauze ban-
dages eliminated structural irregularity and provided an easy to
wrap wound dressing. The mesh was crosslinked, and its efficacy
was investigated in white pig models with similar pathophysi-
ology of burn wounds to humans. The result was compared to
untreated wound, nonloaded mats of Gel_pDA, and silver-based
wound dressings called Aquacel Ag. It was observed that encap-
sulation of Van enhanced the wound closure and led to faster
re-epithelialization, decreased inflammation, and higher kera-
tinization (Figure 8B-I–III). Moreover, pDA crosslinking did not
influence the wound healing process. Van_Gel_pDA (Figure 8B-
IV-z) showed less number of inflammatory cells compared to the
untreated (Figure 8B-IV-x) and non-loaded mat (Figure 8B-IV-y),
and exhibited signs of connective tissue remodeling. How-
ever, silver loaded dressing proved to have fewer inflammatory
cells and a confluent epithelial layer compared to untreated,
non-loaded and loaded wound dressings (Figure 8B-IV-w).[276]
Microfibers have also been utilized to fabricate wound care
products. Melt spun fibers from acrylonitrile-co-1-vinylimidazole
(AN/VIM) copolymer to release nitric oxide (NO) were fabricated
to enhance the wound healing process. NO plays an important
role in stimulation of collagen deposition and angiogenesis dur-
ing the wound healing process. A 12–24 h delay in the NO re-
lease showed to be ideal in the wound healing process as this
factor could accelerate the transition of the inflammatory to the
proliferative phase. To produce the NO donating group, the di-
azeniumdiolate (NONOate), melt-spun AN/VIM fibers were re-
acted with NO at a constant pressure of 4 atm for 1 h. As a result,
the NONOate formed on acrylonitrile segments of fibers, where
each NONOate released two molar equivalents of NO upon reac-
tion with a proton source. In addition, to extend the release time
of NO-loaded AN/VIM fibers, they were dip-coated in a solution
of PCL and chloroform (2 w w–1%). The coating created an evenly
distributed porous layer along the entire surface of the fibers. Af-
ter 3 days, the PCL coated melt-spun AN/VIM copolymer fibers
released a total of 84 µmol NO g–1, while uncoated fibers released
91 µmol NO g–1 in 3 h.[277]
Eventually, modification of the experimental set-up in terms of
the fiber production methods, the type materials and drugs, and
the employed release mechanisms leads to well-structured nano-
or microfibrous textiles with a high surface-to-volume ratio and
interconnected pore structures to support tissue regeneration
and remodeling, and to assist gas exchange and bioactive agents
supply. A review of studies in which drug-eluting constructs are
used for wound care application is summarized in Table 2.
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Figure 8. Applications of drug-loaded fibrous structures. A) Wound care, tissue engineering, and transdermal drug delivery applications using drug-
loaded fibers. B) In vivo wound healing efficacy of antibacterial wound dressing made of Van_Gel_pDA in a pig model, (I) Relative wound closure of
different groups at 46 d post-injury. Obvious impact of Vanco_Gel_pDA on wound closure rate in comparison with non-loaded nanofibers of Gel_pDA
and untreated wounds. (II) Images indicating the condition of the wounds before the debridement at different days (0, 4, 7, 46). The wound surface
showed moderately dry and decreased pus creation in Van_Gel_pDA mats and Aquacel Ag cured wounds, (III) Average wound closing (cm2) for Gel_pDA
(red bars) and Van_Gel_pDA (blue bars) medicated wounds proved that loading the antibiotics enhanced the wound healing and re-epithelialization, (IV)
Histological changes during wound healing after burn injury, (x) Untreated control; Injuries treated with (y) Gel_pDA, (z) Van_Gel_pDA, and (w) Aquacel
Ag. Epidermis (E), dermis (D), inflammatory cells (M), and the blood vessels (arrows) are indicated in the figure. Scale bar = 100 µm. Reproduced with
permission.[276] Copyright 2017, Elsevier. C) (I) Schematic representation of the cell size, (II) cell size on various categories of scaffolds (N = 10), (III)
schematic illustration of the cell promotion angle between the cell growth direction and the fiber parallel direction (x axis), (IV) cell proliferation angle on
various scaffolds (N = 10), and V) Cell viability (N = 3). * and ** exhibited remarkable difference at p < 0.05 and p < 0.01, respectively, (VI) CLSM images
of osteoblasts on a) PLLA, b) PLLA–collagen, and c) PLLA–chitosan aligned scaffolds, respectively. Cell nuclei are shown in blue and actin fibers in red.
Reproduced with permission.[297] Copyright 2013, the royal society of chemistry. D) (I) PVA nanofibers fabricated utilizing optimum point parameters and
processed SEM in similar conditions, (II) Curcumin loaded release into PBS buffer (dashed curve) and NaCl solution (solid curve), (III) Adipose tissue
imaging using MRI in (x) untreated rats versus (y) treated rats by the transdermal patch. Reproduced with permission.[318] Copyright 2018, Elsevier.
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Macromol. Biosci. 2021, 2100021 2100021 (22 of 31) © 2021 The Authors. Macromolecular Bioscience published by Wiley-VCH GmbH
www.advancedsciencenews.com www.mbs-journal.de
6.2. Tissue Engineering
Tissue engineering requires the generation of biological alter-
natives to restore and regenerate damaged tissues.[278,279] Tis-
sue engineering involves utilization of a biodegradable ma-
trix, so-called scaffold, sometimes loaded with pharmaceutical
agents and/or cells in order to assist the three-dimensional tissue
development.[280–283] Drug-eluting scaffolds have been fabricated
based on nonwoven and woven structures. Electrospun nonwo-
vens have been well studied for regenerative medicine and tissue
engineering applications since an ultrafine fibrous network with
high surface-to-volume ratio resembles the natural extracellular
matrix.[132,284–286] Nonwoven fabrics with the capability to deliver
bioactive components, such as antibiotics, growth factors, and
chemotherapeutic agents, have proven to accelerate or inhibit cer-
tain activities during tissue regeneration and remodeling.[4]
Release of encapsulated bone morphogenetic proteins growth
factor from electrospun composite scaffolds made of silk fi-
broin/PEO or poly(d,l-lactide-co-glycolide)/hydroxylapatite
(PLGA/HAp) accelerated osteogenesis and nerve regeneration
processes.[287,288] In another study conducted by Bide and co-
workers, endothelialization was promoted to reduce thrombus
formation by immobilizing vascular endothelial growth fac-
tor and an anticoagulant agent on the surface of the knitted
polyester grafts.[289] Although electrospun constructs have been
vastly used for tissue engineering applications, cell infiltration
through the nanofiber is still the major limitation of this method
due to their small pore sizes. Particle leaching and sacrificial
nanofibers are the two proposed solutions to overcome this
issue.[290] Removing long molecular polymer chains of sacrificial
fibers might be more difficult compared to the leaching particles
but leads to better interconnected pores between the fibers.[291]
Nonwoven wet-spun fibers from natural-based polymers,
such as chitosan,[292,293] starch-based,[294] and PLLA,[295] have
also been used for the fabrication of scaffolds. In a study, wet-
spinning and electrospinning were used for preparing fibrous
bioactive scaffolds to stimulate bone regeneration. The fibrous
scaffold was made of a solution of biodegradable three-arm
branched-star PCL, hydroxyapatite nanoparticles (HNPs), and
clodronate (CDE), a bisphosphonate anti-inflammatory drug
that has revealed effectiveness in the healing of different bone
diseases, including osteoporosis and hyperparathyrosis. To
introduce physical binding between CDE and HNP, Cde–HNP
complex particles were developed to obtain a better control over
drug release and enhance osteoconductivity due to the presence
of the inorganic phase.
In both wetspun and electrospun nonwoven structures, addi-
tion of HNPs, CDE, or CDE-HNPs changed the morphology and
caused aggregation of the particles that were not loaded into the
fibers. In addition, in contrast to the unloaded fibers, the surface
porosity of wet spun CDE–HNP loaded fibers were decreased,
and the fibers did not exhibit binding at the bonding points. For-
mation of the defects induced by loading was minimized by opti-
mizing the spinning conditions, mainly increasing the solution
feed rate. Finally, it was suggested to study a system composed of
a combination of the electrospun and wet-spun fibers in a mod-
ulated ratio into a multiscale fibrous structure to keep a balance
between the material binding sites to the cell membrane recep-
tors and the release kinetics.[296]
Melt spinning can be a helpful method to produce scaffolds
in a scalable, rapid, and solvent-free process. For instance, melt-
spun aligned PLLA fibers glued by 5% PLLA tetrahydrofuran so-
lution were fabricated to obtain fiber-aligned scaffolds to imitate
the morphology of collagen fibrils. The fibers were coated with
collagen and chitosan to achieve the biochemical and surface-
aligned topography cues. In the case of coated fibers, viability,
adherence, length, and migration functioning of osteoblasts were
enhanced in vitro. The aligned fibrous scaffold coated with colla-
gen had the most significant cell length and migration rate, and
the osteoblasts favorably relocated and adhered across the parallel
fiber direction (Figure 8C-II).
However, the cell directional growth angles on the PLLA and
coated fibrous scaffolds showed no significant difference (Fig-
ure 8C-IV). The cell viability on the coated fibers was higher than
pure PLLA fibers after the first and seven days of measurement
(Figure 8C-V). Confocal laser scanning microscopy proved that
osteoblasts cells were adhered and grew on the fibers, while the
untreated fibers had weaker interaction with the cells due to the
presence of a random and irregular distribution of actin fibers.
Coated fibers displayed more robust cell-substrate interaction,
and stressed actin fibers were established in the cells, specifi-
cally in the fibers coated with collagen (Figure 8C-VI). This in-
dicates the potential of the coated fibrous constructs as a suitable
biomimetic microenvironment for osteoblast growth and bone
regeneration.[297]
As a result, surface topography and morphology of the fiber
scaffolds, such as diameter, pattern, and pore size, have an es-
sential role in regulating cell behaviors.[281,298,299] In general, the
larger specific surface area of the fibers will make a higher ratio of
the functional groups of the polymer chains exposed to the tissue.
Consequently, more accessible binding sites to cell membrane
receptors are present to enhance cell adhesion and growth.[300]
The aforementioned features also influence the solute transport
mechanism, which will facilitate the drug release and the rate of
material degradation.[301]
Although the electrospun meshes mimic the ECM structure
and stimulate the tissue growth and remodeling, the pore sizes
are usually in the nanometer scale and can hinder cell infiltration
through the fibrous system, which leads to an undesired tissue
growth besides the burst effect of the drugs due to the high
surface-to-volume ratio.[80] This emphasizes the necessity of
microfabrication processes, including wet- or melt-spinning.
Ultimately, combining the advantages of micro and nanofiber
production helps to obtain a fibrous construct with better
properties required for tissue engineering applications. Table 2
provides examples of drug-loaded fibrous systems for tissue
engineering application.
6.3. Transdermal Drug Delivery
Transdermal fibrous systems can deliver bioactive materials
across the skin in a sustained manner.[302] However, not many
commercial transdermal drug-eluting systems have been in-
troduced. The reason is mainly due to the impermeability of
the stratum corneum, the external layer of skin. Therefore,
drug molecule size cannot exceed more than 400–500 Da, and
should have a balance of lipophilicity, log octanol–water partition
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coefficient around 2 to 3 ideally, to be incorporated into the
bloodstream.[302,303] In the case of larger molecules, micronee-
dles are mounted into transdermal systems so that the drugs
can bypass the skin layers mechanically.[304,305]
To treat various diseases, including superficial nociceptive
pains, such as myalgia and muscular pain, transdermal drug de-
livery methods have been developed based on fibrous structures.
These fibrous drug delivery systems take advantage of the mini-
mum required drug dosage and avoid nonspecific site toxicity. A
wide range of release profiles for this application can be governed
by varying different parameters such as bioactive agent/polymer
ratio, fiber shape, diameter, morphology, and combination of mi-
cro and nanofibers.[4,306]
Nonwoven electrospun fibers have been loaded with
bioactive agents using various loading procedures, such as
encapsulation,[307,308] coaxial electrospinning,[309] and chemical
or physical surface modifications.[310] Transdermal electrospun
mats have been fabricated from natural-based polymers, such
as CA, PLA, and PCL. The fibrous constructs for treatment of
local muscular pain and inflammation were loaded with vari-
ous bioactive agents including nonsteroidal anti-inflammatory
drugs (NSAID), such as naproxen, indomethacin, ibuprofen,
and sulindac,[311] vitamins, such as vitamin A and E,[310] top-
ical disinfectants, such as chlorhexidine,[312] and antibiotics
and antimicrobial agents, such as amoxicillin,[313] tetracycline
hydrochloride,[314] ornidazole,[168,315] and N-halamin.[316]
Cellulose micro/nanofiber meshes with 2 and 3 w v–1% were
fabricated by electrospinning of the pulp in an ionic liquid, 1-
butyl-3-methylimidazolium chloride, and subsequently washed
in water for 72 h. Ibuprofen (IBU), with an efficiency of 6%, were
deposited on the fiber surface or trapped in the web porous areas
by immersing the meshes in the IBU solution. During the fabri-
cation process of the low concentration mesh (2 w v–1%), the ionic
liquid could not be washed off rapidly, and the fibers collected on
the water surface were adhered together and created fusing areas.
However, in the meshes with higher concertation of cellulose (3
w v–1%), most fusing areas were disappeared. Furthermore, the
higher concentration led to nano-scale fibers with a diameter of
1 µm or less, and the microscale fibers with a diameter of around
20 µm.
The IBU loading process did not influence the morphology of
the cellulose fibers significantly. The frictional roughness, as an
indication for skin irritation, was not significantly different be-
tween loaded and nonloaded nonwovens. Cell cytotoxicity assay
performed on the nonwoven textiles showed that the normalized
cells viability was more than 80%. The in vitro release studies re-
vealed that 80% of IBU was released within 250 min from both
2% and 3% cellulose concentration meshes. In both meshes,
the initial fast release within 100 min was attributed to the ad-
sorbed surface of the fiber and fused fiber areas. The release ki-
netics based on Korsmeyer-Peppas was performed, and loaded
nonwovens of the 2% and 3% showed typical Fickian diffusion
mechanism (Q2% = 8.35t0.42 (R2 = 0.9388) and Q3% = 18.53t0.26
(R2 = 0.9908)).[317]
Adepu et al. produced a mesh for transdermal drug release
to prevent undesirable toxic burst release of diclofenac sodium
from encapsulated micropatterned CA electrospun nanofibers.
The micropatterning via nylon meshes with 50 and 100 µm size
openings produced a hydrophobic surface which assisted in con-
trolling the initial burst release of the hydrophilic NSAID drug.
The zero-order release profile changed from 30 min for nonpat-
terned mat to 12 h for the micropatterned mat.[262] This study
suggests that fabrication of multilayered hydrophobic mats us-
ing different spinning methods would provide the opportunity
to obtain a zero-order profile for an extended period.
In another example for the treatment of obesity, PVA fibers
were fabricated and impregnated with curcumin encapsulated
gelatin/albumin nanoparticles. The curcumin-loaded fibers form
a fibrous transdermal drug delivery system for reducing the vol-
ume of subcutaneous adipose tissue. The fibers were optimized
in terms of fiber dimension and porosity to achieve minimal drug
diffusion time from the nanofiber matrix to the surface and to
reach the maximum uniformity of the structure to increase the
reproducibility of the drug release (Figure 8D-I).
Curcumin release profile was investigated in phosphate-
buffered saline (PBS) and NaCl solution to simulate skin sweat-
ing in the existence of a transdermal mesh, where a burst release
profile was observed in both solutions. NaCl solution reached a
higher maximum release percent, more than 80% in less than
150 min, due to higher solubility of PVA and gelatin in water
(Figure 8D-II). Whereas ex vivo transdermal test in a diffusion
cell system using rat abdomen skin sample displayed a differ-
ent profile with a delay in release rate in which the drug release
reached 50% after 20 h.
The fast drug release was explained by the fact that the tar-
geted tissue was below the skin and that the hydrophobic nature
of the drug avoided quick evacuation of adipose tissue into the
bloodstream. In vivo animal tests were conducted on the rats
with high-calorie diets, and the results were analyzed by mag-
netic resonance imaging scans (MRI) and blood tests of leptin,
triglyceride, and cholesterol. The results indicated that the vol-
ume percentage of adipose tissue in the treated group decreased
significantly (4–7%), compared to the obese animals (Figure 8D-
III).[318]
In between all the techniques used for fabrication of the drug-
eluting transdermal textiles, electrospinning is the most stud-
ied one since it is a simple and cost-effective method. Moreover,
unique characteristics including a large surface area to volume
ratio, ultrafine fibrous structure, and high porosity with pore
sizes ranging from submicron to nanometer make the electro-
spun nonwoven a suitable carrier for delivering various bioactive
agents. An overview of drug-eluting medical textiles with their
corresponding fiber spinning methods, drug impregnation tech-
niques, release profiles, and kinetics are provided in Table 2.
7. Discussion
In the previous sections, fiber fabrication processes, drug load-
ing methods, release mechanisms, and kinetics were reviewed.
Drug-eluting fibers obtained from various raw materials vary ex-
tensively in terms of their chemistry and therefore performance
characteristics. Moreover, various fabrication methods, such as
melt- or wet-spinning, can be used both in the laboratory or in-
dustrial scales. The fabrication method depends on not only the
raw material and the final application, but also dimension and
shape of the fibers, biocompatibility of the solvent, and the pro-
cessing parameters.[325,326] Woven and nonwoven structures from
a broad range of natural to synthetic polymers or a combination
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of them have been used in various biomedical applications, such
as wound care, tissue engineering, and regenerative medicine,
due to features such as a high surface area to volume ratio, porous
structure, and surface modification and functionalization.
Bioactive agents could also be loaded into fibers both in pre-
and post-fabrication stages. However, loading methods should be
selected based on the parameters such as bioactive agent chem-
istry, optimal release profile, technical complexity of the spinning
process, and the final application to avoid undesired results in-
cluding low drug efficiency, degradation of the bioactive agents,
poor mechanical properties, drug burst effect, and toxicity.[99]
Mathematical models proposed to describe, quantify, and predict
the kinetics of drug release can help to portrait a better picture of
the drug release profiles; however, it should be realized that most
models have been investigated based on laboratory-driven data
with limitations compared to real conditions. Therefore, there is
a demand to overcome the simplifications of these models by ver-
ifying and improving them with drug release data obtained from
fibrous constructs in real applications.[42]
Recently, scientists have produced functional fibrous struc-
tures with the possibility of sensing the physiological data of
the tissue and the ability to control drug delivery profiles.[327,328]
Nanoscale sensors can be embedded into the medical textiles to
enable a programmable responsive drug delivery system to tune
the release profile of the bioactive agent.[132] The drug release
can be triggered by environmental stimuli, such as pH,[329,330]
temperature,[331] and chemical reactions or external stimuli, such
as the magnetic field,[332] electric field,[333] and light.[334] For ex-
ample, various metals including gold, silver, magnesium, and
zinc can be patterned with low-temperature radiofrequency sput-
tering on the nanofibrous meshes to apply thermal stimulation
to elute antibiotics when needed.
The stimulation can be manipulated via wires or wireless de-
vices, such as smartphones. The use of smart textiles has been
mainly investigated for wound dressing applications where inte-
grated sensors could provide information on the healing status
and the wound environment concerning its pH, bacterial level,
tissue oxygenation, and inflammation.[335] The need for devices
that can provide diagnostic information of the wound status and
combat the infection is growing. However, improving sensor in-
corporation onto the fibrous network, stable sensors, and reliable
networks for data management are required.[335]
The majority of studies reviewed in this article involve in vitro
investigations of the drug-loaded fibers using different kinds of
kinetic models. However, drug release and kinetics studies in vivo
and in a “physiologically relevant” environment are very essential
to move forward towards clinical studies and commercialization
of the fibrous drug delivery systems.
Designing proper methods to fabricate drug-eluting textiles
requires not only a sound understanding of the fabrication
and loading techniques but also the theoretical perception of
human physiological systems and their biological mechanisms.
Engineering databases and the mathematical stimulations could
be evolved for advanced computer-aided textile design by consid-
ering different physiological processes and the physicochemical
functions of the textiles.[336] This can lead to achieving technical
solutions with timely and cost-effective designs.
Finally, it should be noted that despite all the progress in the
field of drug-eluting fibrous systems, there are still some limita-
tions that should be addressed. For example, initial burst release
of the drugs from fibers or aggregation of drug molecules on the
surface of fibers can lead to undesired results. Using smart medi-
cal textiles and triggered drug-release systems could be applied to
overcome some of the shortcomings of the current fibrous drug
delivery systems. Lastly, due to the interdisciplinary nature of this
field, fabrication of a functional drug-eluting fibrous system with
a desired release profile requires the joint efforts of experts from
different disciplines such as chemistry, biology, and engineering.
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